Chewy to acquire SmartEquine from Covetrus in all-cash deal

Chewy, Inc. (NYSE: CHWY) has signed a definitive agreement to acquire SmartEquine, a subsidiary of Covetrus, Inc., in an all-cash transaction that cements Chewy’s entry into the equine health segment and allows Covetrus to streamline its veterinary technology operations. The acquisition, expected to close in the fourth quarter of 2025 pending regulatory approvals, underscores Chewy’s ambition to extend its pet-health ecosystem beyond small animals into higher-margin, subscription-driven equine wellness.

Covetrus, a global provider of technology-enabled veterinary solutions, described the sale as part of its broader plan to sharpen focus on practice-management software, integrated logistics, and data analytics platforms that support veterinarians. By divesting SmartEquine, the company signals a strategic return to its B2B roots — prioritizing digital infrastructure over consumer-facing retail. For Chewy, the deal represents more than an expansion; it is an entry into a market defined by loyalty, high average order value, and recurring supplement subscriptions.

Why Chewy’s move into equine health redefines its long-term growth trajectory

Chewy’s acquisition of SmartEquine, previously known as SmartPak before its rebrand in mid-2025, represents a calculated leap into a historically underserved but lucrative niche. SmartEquine operates one of the most recognized equine supplement and wellness subscription platforms in North America, offering tack, gear, and health products for horses. Chewy intends to leverage its fulfillment network, customer-data insights, and marketing scale to accelerate SmartEquine’s growth while integrating the platform into its larger pet-wellness ecosystem.

According to company disclosures, the acquisition will be financed entirely with existing liquidity, signaling Chewy’s confidence in its cash-generating ability and disciplined capital management. The transaction is expected to be accretive to adjusted EBITDA margins within the first fiscal year following completion. Executives familiar with the matter said Chewy viewed SmartEquine as “a brand with deep emotional resonance and recurring revenue potential,” aligning with the company’s broader strategy of deepening engagement through health products, pharmacy, and insurance services.

For Covetrus, the divestiture marks a clean exit from a consumer segment that, while profitable, diverted focus from its enterprise offerings. The company plans to redeploy capital into its core technology stack — spanning veterinary data platforms, e-prescription systems, and cloud-based practice-management software. By doing so, Covetrus aims to reinforce its leadership in the digitization of veterinary care, particularly in predictive diagnostics and telehealth integration.

How Chewy’s financial performance and investor sentiment frame this acquisition

Chewy reported second-quarter fiscal 2025 net sales of roughly $3.1 billion, an 8.6 percent year-over-year increase, driven by gains in Autoship subscriptions and margin expansion in private-label wellness products. Gross margin climbed to 30.4 percent, while adjusted EBITDA margin reached 5.9 percent — both figures marking steady improvements amid a challenging retail environment. Active customers grew to 20.9 million, up 4.5 percent, with net sales per active customer rising 5 percent to $591.

Following the acquisition announcement, Chewy’s stock rose by roughly 2.2 percent during mid-day trading, according to Investing.com data. Analysts viewed the deal as strategically sound and complementary, noting that it taps into an affluent, high-engagement demographic that tends to spend consistently across subscription cycles. Market observers also highlighted that the equine category offers pricing resilience — horse owners often maintain premium purchases even during consumer downturns, making it an attractive addition to Chewy’s portfolio mix.

Investor sentiment toward Chewy has improved modestly through 2025 as the company continues to balance profitability with long-term expansion. The firm’s disciplined approach to marketing spend and logistics optimization has drawn favorable comparisons to Amazon’s early retail scaling phase. Analysts at Raymond James noted that Chewy’s ability to convert operational leverage into recurring-margin growth could “re-rate the stock upward” if the equine segment delivers anticipated synergies within the first 12 months post-closing.

Why Covetrus’s divestiture strategy signals a shift toward digital-first veterinary innovation

Covetrus’s sale of SmartEquine underscores a strategic evolution away from retail exposure toward high-value technology services. Since its 2022 take-private transaction by Clayton, Dubilier & Rice and TPG Capital, Covetrus has emphasized digitization of veterinary workflows, telemedicine integration, and data-driven diagnostics. The company’s leadership described the divestiture as an intentional narrowing of scope — consolidating around solutions that enable veterinarians to improve patient care through software interoperability, automation, and data analytics.

Industry analysts have observed that Covetrus’s model is converging toward that of a “SaaS-based health infrastructure firm” rather than a traditional distributor. By divesting SmartEquine, Covetrus frees up both operational focus and capital allocation for R&D and cloud expansion. Observers suggest the firm may pursue selective acquisitions in clinical decision-support AI or practice analytics platforms to strengthen its moat.

Meanwhile, the equine business Chewy is acquiring fits neatly into Covetrus’s strategy of exiting lower-synergy retail segments that compete for resources without driving scale economies. Sources close to the company indicated that proceeds from the SmartEquine sale will be partially reinvested into its Covetrus NorthStar cloud suite, which supports over 100,000 veterinarians globally.

How the equine health market could transform under Chewy’s ownership

Equine health remains a niche but premium category within the broader pet economy, valued at approximately $4.8 billion annually in North America. Despite slower overall growth than the companion-pet segment, the equine vertical commands high per-customer spend and long product lifecycles, particularly for nutritional supplements and medical supplies.

By integrating SmartEquine’s subscription base into its e-commerce infrastructure, Chewy gains a captive customer pool with repeat-purchase behavior similar to its successful Autoship model. The company also inherits a data-rich ecosystem that tracks equine health metrics, enabling personalization of recommendations and potential cross-selling into Chewy’s vet-pharmacy services. If executed well, analysts estimate that the equine business could contribute between $250 million and $300 million in incremental annual revenue within three years.

However, challenges remain. Chewy will need to navigate inventory complexity, specialized shipping requirements, and product-education gaps unique to equine owners. It must also retain SmartEquine’s existing brand equity and loyal community, which has been cultivated over two decades. To address this, Chewy plans to maintain SmartEquine’s independent branding under a “powered by Chewy” architecture — a model similar to its integration of PetMD and its pharmacy divisions.

Why this transaction highlights a broader convergence between pet e-commerce and animal-health technology

The Covetrus–Chewy transaction highlights an accelerating convergence between digital retail and health technology in the pet industry. As consumers demand more transparency, automation, and personalization in animal care, major players are increasingly integrating veterinary services, pharmacy solutions, and subscription ecosystems. The acquisition positions Chewy as not just a retailer but a vertically integrated wellness platform spanning multiple species and health categories.

For Covetrus, this divestiture offers renewed clarity of purpose. By concentrating on software and data services for veterinary professionals, the company can compete more directly in the digital transformation of animal healthcare — an arena increasingly defined by interoperability, predictive analytics, and outcome-based service models.

Institutional sentiment surrounding the transaction has been constructive. Analysts view the deal as a “value-unlocking” mechanism that could boost Covetrus’s operational efficiency while providing Chewy a new growth catalyst. The overlap between veterinary-tech digitization and consumer health e-commerce may well define the next phase of expansion across the animal-health sector.

How the Covetrus–Chewy transaction could redefine competitive dynamics between retail scale and veterinary technology platforms

From a capital-markets perspective, Chewy’s acquisition of SmartEquine signals a pivot toward higher-margin vertical integration, while Covetrus’s divestiture reflects strategic discipline in focusing on software and service-based scalability. For investors, the deal reveals contrasting — yet complementary — approaches to growth. Chewy’s balance-sheet strength and omnichannel logistics platform offer leverage for expansion, whereas Covetrus’s leaner focus may improve return on invested capital.

If the integration proceeds as projected, Chewy could set a precedent for other pet retailers seeking specialty verticals with strong brand loyalty and defensible margins. In turn, Covetrus’s transformation into a digital-first infrastructure provider could reshape how veterinary care networks manage data and operational efficiency.